Metastatic Melanoma Clinical Trials
When you look at the numbers, it’s hard to believe: Five-year survival rates for metastatic melanoma have soared from 5% to 10% a decade ago to nearly 50% now. Such changes don’t happen naturally. One of the main drivers of increased survival rates? “Clinical trials,” says Pallavi P. Kumar, M.D., a medical oncologist and director of immuno-oncology at the MedStar Health Cancer Network in Baltimore. “Without the dedication of amazing scientists, doctors, medical staff, and patients, [melanoma] treatments like checkpoint inhibitors and targeted therapies would not be possible.” Lea...
Source: healthcentral.com